HSD17B13

HSD17B13
Identifiers
AliasesHSD17B13, NIIL497, SCDR9, SDR16C3, HMFN0376, hydroxysteroid (17-beta) dehydrogenase 13, hydroxysteroid 17-beta dehydrogenase 13
External IDsOMIM: 612127; MGI: 2140804; GeneCards: HSD17B13
Enzyme activity
EC #BRENDAExPASyKEGGMetaCyc
1.1.1.62↗↗↗↗
1.1.1.105↗↗↗↗
Orthologs
DatabasesNCBI: entry; OMA: entry
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_178135
NM_001136230

NM_001163486
NM_198030

RefSeq (protein)

NP_001129702
NP_835236

NP_001156958
NP_932147

Location (UCSC)Chr 4: 87.3 – 87.32 MbChr 5: 104.1 – 104.13 Mb
PubMed search
Wikidata
View/Edit HumanView/Edit Mouse

17β-Hydroxysteroid dehydrogenase type 13 also known as 17β-HSD type 13 is an enzyme that in humans is encoded by the HSD17B13 gene.

17β-HSD13 is significantly up-regulated in the liver of patients with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis.

Inhibitors

In 2023 the first potent and selective HSD17B13 inhibitor, BI-3231, was reported. The inhibitor meets the quality criteria of a 'Donated Chemical Probe' as defined by the Structural Genomics Consortium.